TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Score IKDC for functional evaluation of the articulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score WOMAC for functional evaluation of the articulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic assessment of osteoarthritis according to absence/presence of pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetics of ASP1941 and Miglitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Percent Cell Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of peripheral hypoperfusion and shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of pulmonary congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The appearance of polymorphic TV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowering the level of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: motor functional testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Radiographic Volume of Thyroid Nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Thyroid Function Assessed by TSH and Free T4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cosmetic Assessment Measured Using a Numerical Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of diabetic foot ulcers healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Detection of lymph node metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Overall Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 2-Year Vital Organ (Heart or Kidney) Deterioration and Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose determination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of omitted critical management steps
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accumulative duration of oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal reattachment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference between actual vs. prescribed dry weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Frequency of grade 3 or higher acute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Aortic uptake of 99mTc tilmanocept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean difference in DXA hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in the concentration of oxyhemoglobin and deoxyhemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Number of Micturition-Related Urgency Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reactive hyperemia index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose limiting toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Cycles completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reclassification of patients as MRD positive at day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Higher sensitivity detection for MRD stratification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical response to fluid administration - SV and/or CO response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment in multiple myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Flow Mediated Vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recanalization of thrombosed vessel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Freedom from endoleak type I or III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Patency of EIA and IIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to reach 5-cell stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for diagnosing lung cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of morphines/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Infant Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of observed toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of entinostat followed by clofarabine
Endpoint domain: Adverse events/effects
Primary endpoint: BMD total body, femoral neck and lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endurance Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular Blood Volume change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Standard Drinks Consumed Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAM-D17 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Combined incidence of all thrombo-embolic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of grade not present in the Los Angeles scale of esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUC(0-τ)ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalography monitoring changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Morbidity and mortality associated with central venous catheter use
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetics of ASP3652 and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ASP3652 alone and in combination
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Emergent Adverse Events (TEAEs) During the Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Emergent Adverse Events (TEAEs) During the Extension Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Serum measurements of IgM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anxiety variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Emotions Recognition Task (TREF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HIV-1 RNA levels <200 copies/mL at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SRK-181
Endpoint domain: Adverse events/effects
Primary endpoint: Biomechanical changes during walking and one-legged hop tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological diagnosis obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major bleeding event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in clinician aggregate weekly milligram morphine equivalents (MME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of treatment emergent adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in clinical laboratory analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in brain MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bronchoalveolar Lavage Fluid Interleukin-8 Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insomnia symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Safety of intravitreal triamcinolone acetonide
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analogue scale of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with negative urea breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visual Reaction Times (V RTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Auditory Reaction Times (A RTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Multiple Choices RTs (MC RTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of large bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent reduction in degree of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic efficacy of mifepristone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity in detection of renal malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Utilization of pain management strategies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: maximum brightness value for visual comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum value of perceptible light contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of light change adaptation (getting dimmer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speed of light change adaptation (getting brighter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion capacity of CO (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall Change in Additional Diagnostic Information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Relevant Laboratory Values at Pre-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Relevant Laboratory Values 24 Hours Post-injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Collagen type 1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathic Pain Scale (NPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McGill Pain Questionnaire-Short Form (MPQ-SF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Global Impression of Improvement Scale (PGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in severity of knee pain on walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of ovarian stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and score of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Sleep Quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: fractalkine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Lactogenesis Stage 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of Highly-effective Contraception
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Peak effect (Emax) for Drug Liking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24 of mifepristone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bystander and abscopal effects
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Depression Rating Scale (HAM-D) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Oral Aperture Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of adverse events and toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Medication Overuse Headaches (MOH) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serological markers of inflammation (CRP, IL-6, TNF-a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: monocyte surface of inflammation and immune response modulating molecules (CD14, CD32, CD44)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: monocytic cells expressing a senescent phenotype (CD14 and CD32)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of neurological sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of usable blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Live Feedback Test Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Shoulder function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent sit-to-stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amblyopic Eye Visual Acuity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in glycated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation of Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Performance on validated metrics for temporal bone surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Coronary angiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inflammatory cytokine secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Recurrent Retinal Detachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Height Standard Deviation Score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Velocity Standard Deviation Score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of an alveolar osteitis
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of Clinical Signs and Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ad Libitum Energy Intake at Buffet Lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reproducibility and repeatability of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal response (MR) and near complete remission (nCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-peptide levels during standard-meal tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postprandial change in blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of menstrual bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 7 point Likert scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in irritable bowel syndrome symptom severity scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity of the iBE device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the iBE device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent signal change in the PCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Still Treated
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Histologic remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of identifying the sentinel lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Percent Improvement in IPSS Over Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days absent from work due to respiratory disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Demonstration of non-caseating granulomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of grade 3 and above non-hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of grade 4 hematologic toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of all grades of peripheral neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Short physical performance battery (SPPB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with meaningful molecular genetic alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with meaningful immunological features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with identification of new tumor-specific genetic characteristics during follow-up (clonal evolution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiation Dermatitis Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in treatment related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Postoperative pediatric anesthesia emergence delirium PAED score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response in patients treated with trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cost of HCV screening and treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sustained Viral Load Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hip and knee joint movements while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: recurrence-free interval (RFI)
Endpoint domain: Mortality/survival
Primary endpoint: Drop of viral load by at least 1 log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent prevalence of kelch13 mutants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of BOS172722
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Report of Adequate Relief From FI Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment-emergent adverse events greater than or equal to Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of fatal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Social Phobia Remission Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of SPBB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes